Avalo Therapeutics
AVTX
64 hedge funds and large institutions have $223M invested in Avalo Therapeutics in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 14 reducing their positions, and 7 closing their positions.
93% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 14
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
24% more capital invested
Capital invested by funds: $180M → $223M (+$42.9M)
5% more funds holding
Funds holding: 61 → 64 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
27% less call options, than puts
Call options by funds: $264K | Put options by funds: $362K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$18.8M |
| 2 |
BlackRock
New York
|
+$3.72M |
| 3 |
Two Sigma Advisers
New York
|
+$2.38M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.48M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$3.86M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.33M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.01M |
| 4 |
SCM
Sio Capital Management
New York
|
-$1.67M |
| 5 |
Renaissance Technologies
New York
|
-$860K |
AVTX Hedge Fund Activity: Q2 2021 in Review
64 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q2 2021, worth a combined $223M — up 24% from $180M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new AVTX positions and 7 closed out — a net gain of 3 holders — while 27 added to existing stakes and 14 trimmed.
The largest buyer was Armistice Capital, adding an estimated $18.8M. The largest seller was Nantahala Capital Management, cutting an estimated $3.86M.
- 64 institutional investors held Avalo Therapeutics (AVTX) as of Q2 2021, up from 61 in Q1 2021.
- Funds reported $223M of Avalo Therapeutics stock for Q2 2021, up 24% quarter-over-quarter.
- 10 funds opened new Avalo Therapeutics positions in Q2 2021 and 7 closed out, a net change of +3 holders.
- The largest Avalo Therapeutics buyer in Q2 2021 was Armistice Capital, an estimated $18.8M added.
- The largest Avalo Therapeutics seller in Q2 2021 was Nantahala Capital Management, an estimated $3.86M sold.
Based on aggregated 13F filings for Q2 2021.